Storia in 17 fonti

GSK compra Nuvalent por 9.200 millones para crecer en oncolog�a

Se trata de la mayor adquisici�n de GSK en m�s de una d�cada y es la primera gran transacci�n del nuevo CEO, Luke Miels, que asumi� las riendas del laboratorio brit�nico el...

Raccontata da

cnbc.com

lecho.be

handelsblatt.com

thehindubusinessline.com

benzinga.com+5 altre

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

expansion.comStai leggendo1 mese fa

GSK compra Nuvalent por 9.200 millones para crecer en oncolog�a

Se trata de la mayor adquisici�n de GSK en m�s de una d�cada y es la primera gran transacci�n del nuevo CEO, Luke Miels, que asumi� las riendas del laboratorio brit�nico el...

originale

Timeline cronologica

martedì 9 giugno 2026·cnbc.com
GSK in talks to acquire Nuvalent for more than $9 billion in biggest deal in over a decade: FT
The deal comes at a time of biotech dealmaking frenzy, driven by looming patent cliffs, newly buoyant public markets and drugmakers' race to bolster pipelines.
martedì 9 giugno 2026·lecho.be
GSK en pourparlers pour racheter Nuvalent pour plus de 9 milliards de dollars
GSK serait en discussions avancées pour racheter la biotech Nuvalent pour 9 à 10 milliards de dollars, selon le Financial Times. L’opération, qui pourrait être conclue dès cette…

GSK compra Nuvalent por 9.200 millones para crecer en oncolog�a

Confronto fonti

GSK compra Nuvalent por 9.200 millones para crecer en oncolog�a

Timeline cronologica

GSK in talks to acquire Nuvalent for more than $9 billion in biggest deal in over a decade: FT

GSK en pourparlers pour racheter Nuvalent pour plus de 9 milliards de dollars

GSK acquires Nuvalent for $10.6 billion to rebuild its oncology business

GSK buys US biopharma company Nuvalent for $10.6B

Gsk acquisisce Nuvalent per 10,6 miliardi nel top deal degli ultimi dieci anni

GSK Boosts Cancer Portfolio, Acquires Nuvalent for $10.6 Billion

GSK Makes Its Biggest Bet In More Than A Decade, Paying $10.6 Billion For Cancer Drug Developer Nuvalent

Nuvalent: GSK übernimmt Krebsspezialisten

Nuvalent: GSK übernimmt Krebsspezialisten für 10,6 Milliarden Dollar

GSK in talks to buy cancer biotech Nuvalent for more than $9 billion

GSK snaps up US cancer treatment firm Nuvalent in $10.6bn deal

GSK to acquire Nuvalent and its two cancer drugs under FDA review for $10.6B

GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B

GSK to buy US lung cancer drug specialist Nuvalent for £8bn

GSK rachète Nuvalent pour plus de 10 milliards de dollars

UK pharma giant GSK to buy US-based cancer drugmaker Nuvalent for $10.6 billion

Gsk sotto pressione a Londra, pesa l'accordo per l'acquisto di Nuvalent

Nuvalent Stock Jumps 39% on Surprise GSK Cancer-Drug Deal

GSK Makes Its Biggest Bet In More Than A Decade, Paying $10.6 Billion For Cancer Drug Developer Nuvalent

GSK compra Nuvalent por US$ 10,6 bilhões e amplia aposta em oncologia

GSK buys US biopharma company Nuvalent for $10.6B

GSK offers 40pc premium in US$10.6b bid for cancer drug developer Nuvalent

Dow Jones Top Company Headlines at 9 AM ET: GSK to Buy Nuvalent for $10.6 Billion in Oncology Push | J.M. ...

Nuvalent vola a Wall Street: titolo in rialzo di quasi il 40% dopo l’annuncio dell’acquisizione da 10,6 miliardi di dollari da parte di Gsk…

Dow Jones Top Company Headlines at 11 AM ET: GSK to Buy Nuvalent for $10.6 Billion in Oncology Push | J.M. ...